Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-24 @ 11:37 PM
NCT ID:
NCT04690556
Eligibility Criteria:
Inclusion Criteria:
1. Ambulatory male or female participants with age ≥ 50 years at the time of screening
2. Capable of understanding and giving written informed consent
3. Primary or recurrent (anti-VEGF naïve) active CNV lesions involving the foveal center secondary to AMD
4. BCVA between 20/40 and 20/200 (Snellen equivalent) in the study eye, using ETDRS testing
5. Willingness and ability to undertake all scheduled visits and assessments
Exclusion Criteria:
1. Known hypersensitivity to ranibizumab or any of the components of study medication
2. Known history of allergy to fluorescein dye
3. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye
4. Subretinal hemorrhage in the study eye that involves the center of the fovea
5. Uncontrolled glaucoma
6. Use of prohibited treatments
Other In-/Exclusion criteria may apply
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT04690556
Study Brief:
Protocol Section:
NCT04690556